Complementary Therapies Enhance Accessibility
Bispecific antibodies and CAR T-cell therapy are complementary and are not in competition with each other. When deciding which to use, the best therapy may be the one that the patient can access.
Payer-Practice Pathway Collaboration Challenges
A major challenge oncology practices have had collaborating with payers in developing pathways is that there are often nuanced differences between the payer pathways and those used by the practice or the network.
Genomic Testing: Valuable Treatment Guidance
Genomic testing is worth the wait to get results to guide treatment—and certainly provides value when balanced against the cost of a therapy that does not work.
Challenges in Rebate Benefits
A highlight of PCOC was a discussion with a health care economist, who explained how pharmacy benefit managers negotiated large rebates, but the benefits of these rebates did not flow to the patients affected by the costs of the therapies.
Financial Toxicity in Clinical Trials
Discussions on financial toxicity showed how even when a patient enrolls in a clinical trial, there may be thousands of dollars in costs not covered by insurance. Financial toxicity must be addressed in a holistic manner.
CO-CHAIR, Vice President, Government Affairs Senior Medical Director, Employer Strategy Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte, CA
CO-CHAIR, Chief Executive Officer Carolina Blood and Cancer Care Associates President Community Oncology Alliance (DC) Rock Hill, SC
KEYNOTE SPEAKER, Former NFL Running Back for the Pittsburgh Steelers & Chicago Bears
FEATURED SPEAKER, Medical Oncologist Tennessee Oncology Murfreesboro, TN
STEERING COMMITTEE, Medical Oncologist Genesis Cancer and Blood Institute Chief Medical Officer American Oncology Network Hot Springs, AK
STEERING COMMITTEE, Vice President, Value-Based Care and Quality Programs Texas Oncology Houston, TX
STEERING COMMITTEE, Director of Pharmacy, Winship Cancer Institute at Emory University, Atlanta, GA
FEATURED SPEAKER, Director of Survivorship Texas Oncology Austin, TX
FEATURED SPEAKER, Assistant Professor, Department of Gastrointestinal Medical Oncology University of Texas MD Anderson Cancer Center Houston, TX
STEERING COMMITTEE, Executive Vice President Minnesota Oncology Maple Grove, MN
STEERING COMMITTEE, Chief Executive Officer OneOncology, Executive Chairman of the Baord, Tennessee Oncology, Nashville, TN
STEERING COMMITTEE, Director, Value-Based Care Optum Sugar Land, TX
- AbbVie
- Adaptive Biotech
- Agilix Health
- AstraZeneca
- BeiGene
- Boehringer Ingelheim Pharmaceuticals
- Bristol-Myers Squibb
- CureMatch
- Dosentrx, Inc.
- GE Capital
- GE Healthcare Financial Services
- Genentech
- Genmab
- Gilead
- GSK
- Humana
- Illumina
- Innovaccer
- Janssen
- KPTI
- Lifespan
- Lilly
- Loxo@Lilly
- Magellan RX Management
- Mayo Clinic
- McKesson
- Menarini Stemline
- Merck & Co.
- Mitsui USA
- Novartis Oncology
- Novartis Pharmaceuticals Corp.
- Oncology Executive
- PatientPoint
- Pfizer Oncology
- Prime Therapeutics
- QCCA Network
- Radiation Business Solutions
- Regeneron
- ReVital Cancer Rehabilitation
- Sanofi
- SpringWorks Therapeutics
- Taiho Oncology
- Texas Oncology
- The Reita Group
- The US Oncology Network
- Thyme Care, Tennessee Oncology
- United Healthcare
- US Oncology Network
- Vanderbilt University Medical Center